1-(2-氯乙酰基)-4-哌啶甲酸乙酯 | 318280-71-6

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 哌啶类
• 中文名称: 1-(2-氯乙酰基)-4-哌啶甲酸乙酯
• 中文别名: 1-(2-氯乙酰基)哌啶-4-羧酸乙酯
• 英文名称: ethyl 1-(2-chloroacetyl)piperidine-4-carboxylate
• 英文别名: ethyl 1-chloroacetylpiperidine-4-carboxylate
• CAS: 318280-71-6
• 化学式: C₁₀H₁₆ClNO₃
• mdl: MFCD01480849
• 分子量: 233.695
• InChiKey: QEHUOCAVXLYCAU-UHFFFAOYSA-N

物化性质

• 沸点：
  345.8±37.0 °C(Predicted)
• 密度：
  1.202±0.06 g/cm3(Predicted)

计算性质

• 辛醇/水分配系数(LogP)：
  1.1
• 重原子数：
  15
• 可旋转键数：
  4
• 环数：
  1.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  46.6
• 氢给体数：
  0
• 氢受体数：
  3

安全信息

• 危险品标志：
  Xi,C
• 危险类别码：
  R20/21/22,R34
• 海关编码：
  2933399090
• 安全说明：
  S26,S36/37/39,S45
• 包装等级：
  III
• 危险类别：
  6.1
• 危险性防范说明：
  P201,P202,P261,P264,P270,P271,P280,P302+P352,P304+P340,P308+P313,P310,P330,P361,P403+P233,P405,P501
• 危险品运输编号：
  2810
• 危险性描述：
  H301,H311,H331,H341
• 储存条件：
  室温

SDS

Name:	Ethyl 1-(2-chloroacetyl)-4-piperidinecarboxylate 97% Material Safety Data Sheet
Synonym:
CAS:	318280-71-6

Section 1 - Chemical Product MSDS Name:Ethyl 1-(2-chloroacetyl)-4-piperidinecarboxylate 97% Material Safety Data Sheet
Synonym:

---

Section 2 - COMPOSITION, INFORMATION ON INGREDIENTS

CAS#	Chemical Name	content	EINECS#
318280-71-6	Ethyl 1-(2-chloroacetyl)-4-piperidinec	97%	unlisted

Hazard Symbols: C
Risk Phrases: 20/21/22 34

---

Section 3 - HAZARDS IDENTIFICATION
EMERGENCY OVERVIEW
Harmful by inhalation, in contact with skin and if swallowed. Causes burns.
Potential Health Effects
Eye:
Causes eye burns.
Skin:
Harmful if absorbed through the skin. Causes skin burns.
Ingestion:
Harmful if swallowed. Causes gastrointestinal tract burns.
Inhalation:
Harmful if inhaled. Causes chemical burns to the respiratory tract.
Chronic:
Not available.

---

Section 4 - FIRST AID MEASURES
Eyes: Immediately flush eyes with plenty of water for at least 15 minutes, occasionally lifting the upper and lower eyelids. Get medical aid immediately.
Skin:
Get medical aid immediately. Immediately flush skin with plenty of water for at least 15 minutes while removing contaminated clothing and shoes.
Ingestion:
Do not induce vomiting. Get medical aid immediately.
Inhalation:
Get medical aid immediately. Remove from exposure and move to fresh air immediately. If not breathing, give artificial respiration. If breathing is difficult, give oxygen.
Notes to Physician:
Treat symptomatically and supportively.

---

Section 5 - FIRE FIGHTING MEASURES
General Information:
As in any fire, wear a self-contained breathing apparatus in pressure-demand, MSHA/NIOSH (approved or equivalent), and full protective gear.
Extinguishing Media:
Use foam, dry chemical, or carbon dioxide.

---

Section 6 - ACCIDENTAL RELEASE MEASURES
General Information: Use proper personal protective equipment as indicated in Section 8.
Spills/Leaks:
Absorb spill with inert material (e.g. vermiculite, sand or earth), then place in suitable container.

---

Section 7 - HANDLING and STORAGE
Handling:
Do not breathe dust, vapor, mist, or gas. Do not get in eyes, on skin, or on clothing. Use only in a chemical fume hood.
Storage:
Store in a cool, dry place. Store in a tightly closed container.
Corrosives area.

---

Section 8 - EXPOSURE CONTROLS, PERSONAL PROTECTION
Engineering Controls:
Facilities storing or utilizing this material should be equipped with an eyewash facility and a safety shower. Use adequate ventilation to keep airborne concentrations low.
Exposure Limits CAS# 318280-71-6: Personal Protective Equipment Eyes: Not available.
Skin:
Wear appropriate protective gloves to prevent skin exposure.
Clothing:
Wear appropriate protective clothing to prevent skin exposure.
Respirators:
Follow the OSHA respirator regulations found in 29 CFR 1910.134 or European Standard EN 149. Use a NIOSH/MSHA or European Standard EN 149 approved respirator if exposure limits are exceeded or if irritation or other symptoms are experienced.

---

Section 9 - PHYSICAL AND CHEMICAL PROPERTIES

Physical State: Viscous liquid
Color: pale yellow
Odor: odorless - slight odor
pH: Not available.
Vapor Pressure: Not available.
Viscosity: Not available.
Boiling Point: Not available.
Freezing/Melting Point: Not available.
Autoignition Temperature: Not available.
Flash Point: Not available.
Explosion Limits, lower: Not available.
Explosion Limits, upper: Not available.
Decomposition Temperature:
Solubility in water:
Specific Gravity/Density:
Molecular Formula: C10H16ClNO3
Molecular Weight: 233.69

---

Section 10 - STABILITY AND REACTIVITY
Chemical Stability:
Not available.
Conditions to Avoid:
Incompatible materials.
Incompatibilities with Other Materials:
Strong oxidizing agents.
Hazardous Decomposition Products:
Carbon monoxide, oxides of nitrogen, carbon dioxide.
Hazardous Polymerization: Has not been reported

---

Section 11 - TOXICOLOGICAL INFORMATION
RTECS#:
CAS# 318280-71-6 unlisted.
LD50/LC50:
Not available.
Carcinogenicity:
Ethyl 1-(2-chloroacetyl)-4-piperidinecarboxylate - Not listed by ACGIH, IARC, or NTP.

---

Section 12 - ECOLOGICAL INFORMATION

---

Section 13 - DISPOSAL CONSIDERATIONS
Dispose of in a manner consistent with federal, state, and local regulations.

---

Section 14 - TRANSPORT INFORMATION

IATA
Shipping Name: CORROSIVE LIQUID, N.O.S.*
Hazard Class: 8
UN Number: 1760
Packing Group: III
IMO
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing Group: III
RID/ADR
Shipping Name: CORROSIVE LIQUID, N.O.S.
Hazard Class: 8
UN Number: 1760
Packing group: III

---

Section 15 - REGULATORY INFORMATION

European/International Regulations
European Labeling in Accordance with EC Directives
Hazard Symbols: C
Risk Phrases:
R 20/21/22 Harmful by inhalation, in contact with
skin and if swallowed.
R 34 Causes burns.
Safety Phrases:
S 26 In case of contact with eyes, rinse immediately
with plenty of water and seek medical advice.
S 36/37/39 Wear suitable protective clothing, gloves
and eye/face protection.
S 45 In case of accident or if you feel unwell, seek
medical advice immediately (show the label where
possible).
WGK (Water Danger/Protection)
CAS# 318280-71-6: No information available.
Canada
None of the chemicals in this product are listed on the DSL/NDSL list.
CAS# 318280-71-6 is not listed on Canada's Ingredient Disclosure List.
US FEDERAL
TSCA
CAS# 318280-71-6 is not listed on the TSCA inventory.
It is for research and development use only.

---

SECTION 16 - ADDITIONAL INFORMATION
N/A

反应信息

• 作为反应物：
  描述：

  1-(2-氯乙酰基)-4-哌啶甲酸乙酯 在 正丁基锂 、 potassium carbonate 作用下， 以 四氢呋喃 、 正己烷 、 乙腈 为溶剂， 反应 14.0h， 生成 3-(1-(2-morpholinoacetyl) piperidin-4-yl)-3-oxopropanenitrile
  参考文献：
  名称：

  [EN] SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS
  [FR] COMPOSÉS PYRAZOLE SUBSTITUÉS À UTILISER EN TANT QU'INHIBITEURS DE SÉRINE PROTÉASE

  摘要：

  提供了一些多取代芳香族化合物，其中包括取代吡唑基，用于抑制凝血酶和/或激肽释放酶。此外，还提供了药物组合物。此外，还提供了一种治疗和预防某些疾病或疾病的方法，这些疾病或疾病可以通过抑制凝血酶和/或激肽释放酶进行治疗或预防。

  公开号：

  WO2016138532A1
• 作为产物：
  描述：

  哌啶-4-甲酸乙酯 、 氯乙酰氯 在 三乙胺 作用下， 以 二氯甲烷 为溶剂， 反应 2.0h， 以61%的产率得到1-(2-氯乙酰基)-4-哌啶甲酸乙酯
  参考文献：
  名称：

  含氯乙酰胺弹头的细菌肽聚糖生物合成酶 MurA 共价抑制剂

  摘要：

  MurA（UDP- N-乙酰氨基葡萄糖烯醇丙酮基转移酶）催化肽聚糖生物合成的细胞质部分的第一个关键步骤，是一种经过验证的抗菌药物发现靶酶；抑制剂磷霉素已在临床上使用了数十年。与磷霉素一样，大多数 MurA 抑制剂是小的杂环化合物，通过与活性位点半胱氨酸形成共价键来抑制酶。反应性氯乙酰胺基团选自一系列合适的亲电硫醇反应性弹头。主要的一步合成导致构建了 47 个片段大小的氯乙酰胺化合物的最终文库。鉴定了几种新的大肠杆菌MurA 抑制剂，其中最有效的化合物具有 IC 50值在低微摩尔范围内。我们文库中所有氯乙酰胺片段的亲电反应性通过高通量分光光度测定法评估，使用还原的埃尔曼试剂作为半胱氨酸硫醇的替代物。LC-MS/MS 实验证实了最有效的抑制剂与消化的 MurA 酶的 Cys115 的共价结合。通过生化时间依赖性测定和稀释测定进一步研究共价结合，证实了不可逆和时间依赖性作用模式。氯乙酰胺衍生物对

  DOI：

  10.1016/j.ejmech.2022.114752

文献信息

• Indoles and 1-(3-(benzyloxy)benzyl)piperazines: Reversible and selective monoamine oxidase B inhibitors identified by screening an in-house compound library
  作者：Damijan Knez、Martina Hrast、Rok Frlan、Anja Pišlar、Simon Žakelj、Janko Kos、Stanislav Gobec

  DOI：10.1016/j.bioorg.2021.105581

  日期：2022.2

  perazine (16 analogues) MAO-B inhibitors were derived from hits, and screened for their structure-activity relationships. Both series yielded low micromolar selective inhibitors of human MAO-B, namely indole 2 (IC50 = 12.63 ± 1.21 µM) and piperazine 39 (IC50 = 19.25 ± 4.89 µM), which is comparable to selective MAO-B inhibitor isatin (IC50 = 6.10 ± 2.81 µM), yet less potent in comparison to safinamide

  单胺氧化酶 A 和 B（MAO-A 和 MAO-B）抑制剂的治疗适应症来自对神经和肿瘤疾病的动物和细胞模型的生物学研究，已将药物发现项目集中在识别可逆的 MAO 抑制剂上。对我们内部学术化合物库的筛选确定了两种抑制 MAO-B 的热门化合物，IC 50值在微摩尔范围内。两个系列的吲哚（23 个类似物）和 3-（苄氧基）苄基）哌嗪（16 个类似物）MAO-B 抑制剂来源于命中，并筛选了它们的构效关系。这两个系列均产生了低微摩尔选择性人 MAO-B 抑制剂，即吲哚2 (IC 50 = 12.63 ± 1.21 µM) 和哌嗪39 (IC 50 = 19.25 ± 4.89 µM)，与选择性 MAO-B 抑制剂 isatin (IC 50 = 6.10 ± 2.81 µM) 相当，但与 safinamide (IC 50 = 0.029 ± 0.002 µM)相比效力较低。选择性 MAO-B 抑
• Streptogramin derivatives, their preparation and compositions containing them
  申请人：Aventis Pharma S.A.

  公开号：US06569854B1

  公开（公告）日：2003-05-27

  Group A streptogramin derivatives of general formula (I) in which: R1 represents a halogen atom or an azido or thiocyanato radical, R2 represents a hydrogen atom or a methyl or ethyl radical, R3 represents a hydrogen atom, or the residue of an aliphatic, cycloaliphatic, aromatic, araliphatic, heterocyclic or heterocyclylaliphatic ester which may be substituted, and the bond - - - represents a single bond (stereochemistry 27R) or a double bond, as well as its salts when they exist.

  通用公式（I）中的A组链霉素衍生物，其中： R1代表卤素原子或偶氮基或硫氰基， R2代表氢原子或甲基或乙基基， R3代表氢原子，或脂肪、环脂、芳香、芳基脂肪、杂环或杂环脂肪酯的残基，可能被取代， 连接- - - 代表单键（立体化学27R）或双键， 以及存在时的盐。
• 一种具有抗肿瘤活性的莪术醇衍生物及其制 备方法和应用
  申请人：辽宁大学

  公开号：CN106674242B

  公开（公告）日：2018-11-30

  本发明涉及一种具有抗肿瘤活性的莪术醇衍生物及其制备方法和应用。属于医药技术领域，涉及通式Ⅰ所示的具有抗肿瘤活性的新化合物。本发明还涉及所述化合物的制备及用途，本发明以简单易得的天然产物莪术醇为原料，通过半合成的方法，设计并合成了一系列具有抗肿瘤活性的莪术醇衍生物，并在体外实验显示出了较好的抗肿瘤活性，可以通过进一步的实验将此类化合物应用于抗肿瘤药物研究。
• Cyclische Harnstoffderivate, diese Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung
  申请人：Dr. Karl Thomae GmbH

  公开号：EP0587134A2

  公开（公告）日：1994-03-16

  Die Erfindung betrifft cyclische Harnstoffderivate der allgemeinen Formel in der Ra, Rb, X und Y wie im Anspruch 1 definiert sind, deren Tautomere, deren Stereoisomere und deren Salze, insbesondere deren physiologisch verträgliche Salze mit anorganischen oder organischen Säuren oder Basen, welche wertvolle pharmakologische Eigenschaften aufweisen, vorzugsweise aggregationshemmende Wirkungen, die Verbindungen enthaltende Arzneimittel und Verfahren zu ihrer Herstellung.

  本发明涉及通式如下的环状脲衍生物 其中 Ra、Rb、X 和 Y 如权利要求 1 所定义；它们的同分异构体、立体异构体和它们的盐，特别是它们与无机或有机酸或碱的生理相容盐，它们具有宝贵的药理特性，最好是抗聚集作用；含有这些化合物的药物和它们的制备工艺。
• SUBSTITUTED PYRAZOLE COMPOUNDS AS SERINE PROTEASE INHIBITORS
  申请人：Verseon Corporation

  公开号：EP3261639A1

  公开（公告）日：2018-01-03